Ray Therapeutics Tackles a Rare Blinding Disease With $100 Million in Financing

▤ Summary

Venture investors have provided $100 million in fresh funding to Ray Therapeutics, a biotech company seeking to restore vision in people with the rare blinding disease retinitis pigmentosa.San Francisco-based Ray Therapeutics is one of several startups harnessing advances in gene therapy to attack retinitis pigmentosa. Other companies are aiming to stem the disorder before it results in blindness, among them Paris-based SparingVision and Eudora, a startup launched by San Diego- and London-based biotech company Replay Holdings.

▦ Linked Companies